Pure Global AI
NCT06265623Not yet recruiting

Intermittent Hypoxemia, Lung Function Decline, Morbidity, and Mortality in COPD (PROSA Study).

Prospective Observational Study to Assess the Influence of Intermittent Hypoxaemia on Lung Function Decline, Morbidity, and Mortality in COPD Patients (PROSA Study)
Universitätsklinikum Hamburg-EppendorfClinicalTrials.govother
Verified
Study focus
Disease/Condition
Chronic Obstructive Pulmonary Disease (COPD)
Drug/Device/Intervention
No active intervention, but observational follow-up
Study type
Observational
Intervention type
other
Sponsor & location
Primary sponsor
Universitätsklinikum Hamburg-Eppendorf
Location
Hamburg, Germany
Timeline & enrollment
Phase
N/A
Start date
Mar 01, 2024
End date
Sep 30, 2029
Enrollment
148 participants
Primary outcome

Difference in FEV1(% of LLN) between baseline and end-of-follow-up

Summary

This study aims to analyze if patients with chronic obstructive lung disease who experience a
 decline of blood oxygen saturation during physical exercise have a disease course different
 from that of COPD patients who do not experience a decline in blood oxygen saturation during
 exercise. Patients will be followed for a total of 3 years.

ICD-10 classifications
Other chronic obstructive pulmonary diseaseChronic obstructive pulmonary disease, unspecifiedOther specified chronic obstructive pulmonary diseaseChronic obstructive pulmonary disease with acute exacerbation, unspecifiedChronic obstructive pulmonary disease with acute lower respiratory infection
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06265623
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06265623 through Pure Global AI's free database. This phase not specified trial is sponsored by Universitätsklinikum Hamburg-Eppendorf and is currently Not yet recruiting. The study focuses on Chronic Obstructive Pulmonary Disease (COPD). Target enrollment is 148 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.